Pratt Collard Advisory Partners’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$2.7M Sell
21,754
-139
-0.6% -$17.5K 1.8% 15
2021
Q1
$2.59M Sell
21,893
-1,060
-5% -$124K 1.85% 14
2020
Q4
$2.69M Sell
22,953
-450
-2% -$49.5K 1.96% 11
2020
Q3
$2.43M Sell
23,403
-525
-2% -$52.7K 1.99% 12
2020
Q2
$2.19M Buy
23,928
+107
+0.4% +$10.3K 1.97% 14
2020
Q1
$2.15M Sell
23,821
-537
-2% -$57.1K 2.16% 12
2019
Q4
$2.76M Sell
24,358
-156
-0.6% -$17.1K 2.11% 11
2019
Q3
$2.66M Buy
24,514
+65
+0.3% +$6.78K 2.1% 10
2019
Q2
$2.38M Sell
24,449
-824
-3% -$75.2K 1.88% 13
2019
Q1
$2.3M Sell
25,273
-786
-3% -$70.3K 1.84% 14
2018
Q4
$2.37M Buy
26,059
+277
+1% +$25.9K 2.15% 9
2018
Q3
$2.54M Buy
25,782
+100
+0.4% +$9.24K 2.03% 11
2018
Q2
$2.2M Sell
25,682
-300
-1% -$25.1K 1.9% 10
2018
Q1
$2.08M Buy
25,982
+3,013
+13% +$249K 1.82% 11
2017
Q4
$1.85M Buy
+22,969
New +$1.84M 1.53% 17

Other funds holding MDT

Pratt Collard Advisory Partners's MDT Position: Q2 2021 in Review

Pratt Collard Advisory Partners reduced its Medtronic (MDT) stake by 0.63% in Q2 2021, selling an estimated $17.5K and leaving 21,754 shares worth $2.7M. The position accounts for 1.8% of the portfolio, ranked #15.

Pratt Collard Advisory Partners first reported a position in MDT in Q4 2017 and has held it in 15 quarters since. The position peaked at $2.76M in Q4 2019. 2,004 funds tracked by Wall St. Rank hold MDT as of Q2 2021.

  • Pratt Collard Advisory Partners held 21,754 shares of Medtronic worth $2.7M as of Q2 2021.
  • Pratt Collard Advisory Partners sold 139 Medtronic shares in Q2 2021, an estimated $17.5K.
  • Medtronic made up 1.8% of Pratt Collard Advisory Partners's portfolio in Q2 2021, its #15 holding.
  • Pratt Collard Advisory Partners first reported a position in Medtronic in Q4 2017 and has held it in 15 quarters since.
  • Pratt Collard Advisory Partners's Medtronic position peaked at $2.76M in Q4 2019.
  • 2,004 funds tracked by Wall St. Rank held Medtronic as of Q2 2021.

Based on Pratt Collard Advisory Partners's 13F filing for Q2 2021, filed 14 Jul 2021.